由于肿瘤异质性,在EGFR-TKI治疗前,肿瘤组织中可能同时存在NSCLC和SCLC细胞两种成分,但病理组织学活检只找到NSCLC成分,在EGFR-TKI对NSCLC起效的过程中,SCLC的成分逐渐显现出来,并占据主导地位[24]。. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.